The Correction Was Predictable — The Magnitude Was Not
From 2020 through 2023, life science real estate was the darling of commercial construction. Venture capital funding for biotech surged. Pandemic-era urgency drove demand for laboratory and research facilities. And developers, flush with capital and projecting geometric growth curves, broke ground on speculative lab space at a pace the market had never seen. The data was clear: lab construction starts increased 180% between 2020 and 2023, and lab rents in gateway markets reached $100 to $130 per square foot triple-net — rivaling Class A office in Manhattan.
The numbers tell a different story in 2026. Lab space construction demand has dropped 28% year-over-year, as measured by new construction starts and owner-initiated project commitments. Lab vacancy rates in the three primary markets — Boston/Cambridge, San Francisco Bay Area, and San Diego — have risen from near-zero in 2022 to 18%, 22%, and 15% respectively. And sublease availability has tripled, as biotech tenants who leased aggressively during the boom now shed space to manage cash burn.
This is not a collapse. It is a correction — a market returning to equilibrium after a speculative overshoot. But the magnitude of the correction demands analysis, because it carries lessons for developers, contractors, and investors across the commercial construction spectrum.
The Anatomy of a Bubble
The life science construction bubble inflated through a familiar mechanism: abundant capital seeking differentiated real estate exposure found a sector with a compelling demand narrative and limited existing supply. The sequence was textbook.
Phase 1 (2020-2021): Legitimate demand surge. COVID-19 created genuine urgency for vaccine development, therapeutic research, and diagnostic production capacity. Biotech venture capital funding reached $38 billion in 2021 — more than double the 2019 level. Companies that raised capital needed lab space to deploy it, and existing lab inventory in the gateway markets was essentially fully leased. Rents rose 20% to 30%, and build-to-suit projects filled immediately.
Phase 2 (2021-2022): Developer response. Observing the supply-demand imbalance, developers launched a wave of new construction and conversion projects. Ground-up lab buildings and office-to-lab conversions began at an unprecedented pace. In the Boston/Cambridge market alone, 12 million square feet of lab space was under construction by mid-2022 — representing a 28% increase in total market inventory.
Phase 3 (2022-2023): Speculative overshoot. The development pipeline exceeded what tenant demand could absorb, but capital continued to flow because lab space rents were high and rising, making the development economics appear favorable. Developers broke ground on speculative projects — lab buildings without pre-committed tenants — based on projections that demand growth would continue at pandemic-era rates.
Phase 4 (2024-2026): Correction. Biotech venture funding declined 42% from its 2021 peak, and companies that raised capital during the boom began to conserve cash as the funding environment tightened. Tenant demand for new lab space slowed dramatically, and the speculative space that had been under construction began delivering into a market with declining absorption. The result: rising vacancy, falling rents, and a 28% reduction in new construction starts.
The Data in Detail
The key metrics that define the current lab space market tell a consistent story of oversupply:
Vacancy rates by market. Boston/Cambridge: 18.2% (up from 2.1% in Q4 2021). San Francisco Bay Area: 22.4% (up from 3.8%). San Diego: 15.1% (up from 4.2%). Research Triangle, North Carolina: 11.3% (up from 5.6%). New Jersey Corridor: 13.8% (up from 7.2%). National average: 16.5%.
Sublease availability. Total US lab sublease availability reached 28 million square feet in Q1 2026 — nearly four times the 7.5 million square feet available in Q1 2023. Sublease space typically trades at a 20% to 35% discount to direct lease rates, putting downward pressure on rents across the market and undermining the economics of new development.
Rent trajectory. Average asking rents for Class A lab space have declined 12% to 18% from peak levels in the gateway markets, and effective rents (including concessions) have declined further. Tenant improvement allowances — the landlord contribution to fit-out costs — have increased from $100 to $150 per square foot during the tight market to $175 to $250 per square foot in the current environment, as landlords compete for a shrinking pool of active tenants.
Construction pipeline. Despite the demand decline, approximately 35 million square feet of lab space remains under construction nationally, with delivery dates extending through 2027. This pipeline represents committed capital that cannot be recalled, and much of it will deliver into a market with vacancy rates that may not absorb the new supply for two to three years.
Impact on Construction Contractors
The lab construction slowdown has immediate and measurable effects on general contractors and specialty subcontractors who expanded their lab-building capabilities during the boom:
Reduced bid opportunities. The number of lab construction projects in the bidding and pre-construction phase has declined approximately 35% from peak levels. Competition for remaining projects has intensified, with bid-to-award ratios (the number of firms bidding per project) increasing from 3-to-4 during the boom to 6-to-8 currently.
Margin compression. Increased competition is driving down general contractor margins on lab projects. GC markups that ranged from 4% to 6% during the peak have compressed to 2.5% to 4% for competitive bids. Fee-based arrangements, which were common when contractors had pricing power, are increasingly replaced by competitive hard bids as owners take advantage of the softer market.
Payment risk. Some speculative lab projects that broke ground during the boom are now encountering financing challenges as developers struggle to secure permanent financing for unleased buildings. GCs and subcontractors should conduct enhanced due diligence on project financing — requesting evidence of construction loan availability and equity commitment — before committing resources to new lab projects.
Transition to tenant improvement work. While new construction has declined, lab tenant improvement work remains active as existing tenants reconfigure space and new tenants fit out shell space in speculative buildings. The TI market provides a partial offset to the new construction decline, but TI projects are typically smaller, shorter-duration, and lower-margin than ground-up construction.
Lab Construction Cost Profile
For context, lab construction remains one of the most expensive commercial building types, with costs that reflect the complexity of the building systems:
Shell and core: $350 to $500 per square foot for a purpose-built lab building, including the structural system (designed for higher floor loads than office — typically 100 to 150 PSF live load versus 50 to 80 PSF for office), the building envelope (often incorporating curtain wall with high-performance glazing), and core MEP infrastructure.
Lab fit-out: $200 to $400 per square foot for wet lab space (chemistry and biology labs with fume hoods, gas systems, and specialized plumbing) and $100 to $200 per square foot for dry lab space (computational, physics, and engineering labs with higher electrical and cooling loads but fewer plumbing requirements).
Total developed cost: $550 to $900 per square foot for a fully fitted Class A lab facility — three to five times the cost of comparable office space and seven to ten times the cost of conventional warehouse construction.
These cost levels mean that lab construction projects, even when starts are down 28%, represent a disproportionately large share of commercial construction revenue. A single 200,000-square-foot lab building with a total development cost of $150 million represents more construction revenue than ten conventional warehouses.
What Happens Next
The life science construction market is transitioning from a growth phase to a stabilization phase. Several indicators suggest where the market is heading:
Absorption will gradually catch up with supply. Despite the venture capital pullback, underlying demand for lab space continues — driven by NIH funding (which reached $48 billion in the 2025 appropriation), pharmaceutical company R&D spending (up 6% YoY), and the ongoing maturation of cell therapy, gene therapy, and AI-driven drug discovery platforms. The demand isn't disappearing; it's growing more slowly than the supply that was built for a faster growth rate.
Secondary markets will emerge. The correction is most severe in the three gateway markets that were the primary beneficiaries of the boom. Secondary lab markets — Research Triangle, Denver, Philadelphia, Minneapolis, Nashville — have lower vacancy rates, lower construction costs, and growing tenant demand driven by cost arbitrage. Lab construction activity in secondary markets is expected to grow 10% to 15% annually even as gateway market construction contracts.
Conversion projects will slow or pause. Many of the office-to-lab conversion projects that were planned during the boom have been shelved as the lab market has softened. The conversion pipeline, which peaked at 45 million square feet nationally in 2023, has declined to approximately 20 million square feet. Some planned conversions are pivoting to residential or alternative commercial uses as the lab demand thesis weakens.
Quality differentiation will matter more. In a market with rising vacancy, not all lab space is equal. Modern, purpose-built lab facilities with high ceiling heights, robust MEP infrastructure, and flexible floor plates will outperform older or converted lab space. Tenants in a soft market can choose the best available option, and buildings that were marginal during the boom will struggle to attract and retain tenants.
Lessons for the Construction Industry
The life science construction correction offers broadly applicable lessons:
Speculative construction in specialty building types is inherently risky. Lab buildings are expensive, inflexible, and difficult to repurpose if lab demand fails to materialize. The same logic applies to other specialty building types — data centers, cold storage, semiconductor fabs — that are currently experiencing investment booms. The risk of speculative overbuilding is proportional to the specificity and cost of the building type.
Capital availability is not the same as demand. The fact that developers could raise capital to build lab space did not mean that tenants existed to occupy it. Capital markets are forward-looking and sometimes wrong; construction decisions based solely on capital availability rather than demonstrated tenant demand carry elevated risk.
Market timing matters. Contractors who expanded their lab construction capabilities during the boom and maintained conservative balance sheets are well-positioned to weather the correction. Those who took on fixed overhead — office space, equipment, staff — to support lab construction volume that has declined 28% face a more challenging adjustment.
The life science construction correction is significant but not catastrophic. Lab space remains a technically demanding and financially rewarding building type for contractors who can execute it well. But the era of limitless demand and unlimited capital is over. The numbers tell a different story now — one of discipline, selectivity, and careful attention to the fundamentals of supply and demand.
The Conversion Question
As lab vacancy rises and some speculative lab buildings struggle to attract tenants, the question of converting lab space to other uses — office, residential, or other commercial functions — is gaining relevance. However, the conversion of purpose-built lab space presents significant challenges:
Lab buildings are designed with higher floor-to-floor heights (14 to 16 feet versus 12 to 13 feet for office), more extensive MEP infrastructure (including chemical waste piping, specialty gas systems, and enhanced ventilation), and floor loads that exceed office requirements. While these characteristics don't preclude conversion, they make the process more complex and expensive than typical adaptive reuse.
The most likely conversion path for vacant lab space is "lab-ready" — maintaining the enhanced infrastructure while marketing the space for office use at a premium to conventional office rents. This approach preserves optionality (the space can be converted back to lab use if demand recovers) while generating revenue from the existing building. Lab-ready space typically commands rents of $50 to $70 per square foot — below lab rents of $80 to $130 but above conventional office rents of $35 to $55.
Some developers are exploring residential conversion of lab buildings, though the deep floor plates common in purpose-built lab buildings (80 to 100 feet from core to exterior wall) create significant design challenges for residential use. Residential conversions of lab space are most feasible in buildings with narrower floor plates or where light wells and interior courtyards can be incorporated to provide natural light and ventilation to interior units.
The lab space correction will create opportunities for creative adaptive reuse, but the specialized nature of lab construction means that conversion costs are higher and the range of viable alternative uses is narrower than for more conventional building types. Contractors with expertise in both lab construction and adaptive reuse will be well-positioned to serve this emerging niche as the market adjusts to the new supply-demand reality.
The 28% decline is a market correction, not a structural collapse. The demand for research and development space will continue to grow over the long term, driven by the fundamental human need for medical innovation, technological advancement, and scientific discovery. The numbers will recover — but they will recover to a sustainable level rather than the speculative peak that preceded the correction.
Related Reading
Frequently Asked Questions
Why has lab space construction demand dropped 28%?
Lab space construction starts increased 180% between 2020 and 2023, driven by pandemic-era biotech funding and speculative development in gateway markets. Developers built ahead of actual demand, and by 2025 vacancy rates in the three primary lab markets — Boston/Cambridge, San Francisco Bay Area, and San Diego — had risen to 18%, 22%, and 15% respectively. Sublease availability tripled as biotech tenants shed excess space to manage cash burn as VC funding normalized. New construction starts fell 28% year-over-year as the market absorbed speculative supply.
What were rents at the peak of the lab space boom, and where are they now?
At the peak of the life science boom (2022-2023), lab rents in gateway markets reached $100 to $130 per square foot triple-net — rivaling Class A office in Manhattan. As vacancy has risen, landlords have begun offering concessions and free rent periods that weren't available during the boom. Effective rents (accounting for concessions) have declined 15% to 25% from peak in the most oversupplied submarkets, though headline asking rents have been slower to adjust as landlords hold out for credit tenants.
Are there still viable lab construction opportunities in 2026?
Yes — in specific niches. Build-to-suit projects for anchor tenants with long-term lease commitments continue to get financed. Government-funded research facilities (NIH, DOD, and university-adjacent projects) are less sensitive to speculative market conditions. Manufacturing-scale bioreactor facilities and GMP production spaces, which differ structurally from traditional research labs, face different supply-demand dynamics. The correction is concentrated in speculative multi-tenant lab buildings in overbuilt gateway markets — not in all life science construction.
